Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study

BACKGROUND: C3 Glomerulopathy (C3G) is a rare glomerular disease caused by dysregulation of the complement pathway. Based on its pathophysiology, treatment with the monoclonal antibody eculizumab targeting complement C5 may be a therapeutic option. Due to the rarity of the disease, observational dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Welte, Thomas, Arnold, Frederic, Westermann, Lukas, Rottmann, Felix A., Hug, Martin J., Neumann-Haefelin, Elke, Ganner, Athina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832765/
https://www.ncbi.nlm.nih.gov/pubmed/36631797
http://dx.doi.org/10.1186/s12882-023-03058-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832765/
https://www.ncbi.nlm.nih.gov/pubmed/36631797
http://dx.doi.org/10.1186/s12882-023-03058-9

Ejemplares similares